A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: An Eastern Cooperative Oncology Group study
Argiris A, Goldwasser M, Burtness B, Deconti R, Axelrod R, Van Waes C, Forastiere A. A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: An Eastern Cooperative Oncology Group study. Journal Of Clinical Oncology 2006, 24: 5573-5573. DOI: 10.1200/jco.2006.24.18_suppl.5573.Peer-Reviewed Original ResearchStable diseaseEvaluable ptsNeutropenia 5Cystic carcinomaEastern Cooperative Oncology Group StudyECOG performance status 0Median progression-free survivalGrade 3/4 toxicitiesPerformance status 0Absolute neutrophil countPhase II trialProgression-free survivalTime of progressionAdenoid cystic carcinomaDistant metastatic sitesNF-κB activityAddition of doxorubicinBaseline tumorDiarrhea 5Measurable diseasePrior therapyStatus 0Thrombocytopenia 5Disease stabilizationII trial